CS
BOLD

Credit Suisse’s Audentes Therapeutics, Inc BOLD Stock Holding History

Credit Suisse’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-266,909
Closed -$16M – 4393
2019
Q4 		$16M Buy
266,909
+203,671
+322% +$7.64M 0.01% 1158
2019
Q3 		$1.78M Buy
63,238
+3,350
+6% +$114K ﹤0.01% 2561
2019
Q2 		$2.27M Buy
59,888
+1,111
+2% +$42.7K ﹤0.01% 2372
2019
Q1 		$2.29M Buy
58,777
+8,310
+16% +$238K ﹤0.01% 2275
2018
Q4 		$1.08M Buy
50,467
+28,614
+131% +$738K ﹤0.01% 2720
2018
Q3 		$865K Sell
21,853
-2,088
-9% -$77.8K ﹤0.01% 2963
2018
Q2 		$914K Sell
23,941
-10,592
-31% -$392K ﹤0.01% 3081
2018
Q1 		$1.04M Buy
34,533
+19,820
+135% +$671K ﹤0.01% 2926
2017
Q4 		$459K Buy
14,713
+2,523
+21% +$69.3K ﹤0.01% 3476
2017
Q3 		$341K Buy
+12,190
New +$265K ﹤0.01% 3681

Credit Suisse's BOLD Position: Q1 2020 in Review

Credit Suisse sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 266,909 shares — an estimated $16M sold.

Credit Suisse first reported a position in BOLD in Q3 2017 and held it in 10 quarters. The position peaked at $16M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

  • Credit Suisse reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
  • Credit Suisse sold 266,909 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $16M.
  • Credit Suisse first reported a position in Audentes Therapeutics, Inc in Q3 2017 and held it in 10 quarters.
  • Credit Suisse's Audentes Therapeutics, Inc position peaked at $16M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on Credit Suisse's 13F filing for Q1 2020, filed 13 May 2020.